AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 22 min read$AXSM

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 5:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 6:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

Earnings beat on revenue and loss narrowing may prompt short‑term buying interest.

02

Market read

First earnings disclosure provides fresh data for valuation and trading decisions.

03

What to watch

Third‑party data reporting issue could obscure true prescription trends.

Relevance 8/10Novelty 8/10Timing: after‑hours release

Background

Axsome Therapeutics reported Q3 2026 results, highlighting AUVELITY performance and cash runway.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Q3 2026 earnings call disclosed 52% YoY revenue growth, narrowed net loss to $12.9M and guidance on cash runway.

Expected impact

likely modest upside as market prices in revenue beat and improved loss profile

Evidence & confidence

First‑time disclosure of earnings with solid growth and cash guidance; traders can adjust positions today.

Market effects

Sector

Positive signal for neuroscience/psychiatric drug sector, may lift peers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to investors focused on biotech earnings.

Counterpoint

What could challenge this read

Revenue growth may be unsustainable if label expansion stalls; watch for future discount pressure.

Key entities

  • company
    Axsome Therapeutics, Inc.

    Biopharma focused on CNS disorders.

Read at source← All news

StoryAxsome reports strong Q3 growth as AUVELITY sales accelerate

Also covered by

4 outlets

Related articles

NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMed

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics reported Q3 earnings, with R&D expenses rising to $50.6M and SG&A to $203.1M. AUVELITY prescriptions grew 40% YoY, while SYMBRAVO and SUNOSI also saw increases. The company expects cash to fund operations until cash-flow positivity. Axsome outlined 2027 milestones, including FDA review of AXS-12 and trials for AXS-05, solriamfetol, and AXS-20.

finance.yahoo.com2 min